Yingyu Chen, An Song, Zhiwei Wang, Liyuan Kou, Yan Jiang, Mei Li, Weibo Xia, Ou Wang, Xiaoping Xing
{"title":"Microwave ablation permits an effective and safe treatment for lung metastasis of parathyroid carcinoma: A Retrospective Single-Center Study.","authors":"Yingyu Chen, An Song, Zhiwei Wang, Liyuan Kou, Yan Jiang, Mei Li, Weibo Xia, Ou Wang, Xiaoping Xing","doi":"10.1007/s12020-025-04201-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Metastatic parathyroid carcinoma (PC) is rare and hard to treat. Minimally invasive alternatives to surgery are needed. We aimed to evaluate the effectiveness and safety of microwave ablation (MWA) for lung metastases from PC.</p><p><strong>Methods: </strong>This retrospective study analyzed data from PC patients undergoing percutaneous MWA for lung metastases at a Chinese tertiary hospital. Primary outcomes included changes in corrected serum calcium (ΔCSC) and parathyroid hormone (ΔPTH), with influencing factors being assessed. Adverse events were also recorded.</p><p><strong>Results: </strong>Six patients received 15 MWA procedures for 21 lung metastases. Serum PTH levels decreased by 40.5 ± 21.5%, with a ΔPTH of 321.1 (240.0, 433.0) pg/mL. CSC levels dropped by 0.27 ± 0.25 mmol/L (P = 0.030), normalizing in 66.7% of MWA sessions. Ablated tumor sizes either reduced slightly or stabilized. The time to reach the lowest PTH and CSC levels was 2.0 (1.0, 7.0) days and 3.0 (1.0, 7.0) days, respectively, with effects lasting 31.5 (19.3, 133.0) days for PTH and 14.0 (14.0, 49.0) days for CSC. Fewer metastases (r = -0.539, P = 0.038; r = -0.660, P = 0.007; respectively) and a higher proportion of ablated nodules (r = 0.568, P = 0.027; r = 0.629, P = 0.012; respectively) were associated with greater PTH and CSC reductions. Common complications included mild pneumothorax and mild hemorrhage (20% each), with no adverse events in about half of the sessions.</p><p><strong>Conclusion: </strong>MWA offers a safe and effective option for treating lung metastases in PC patients when surgery is not feasible.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-025-04201-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Metastatic parathyroid carcinoma (PC) is rare and hard to treat. Minimally invasive alternatives to surgery are needed. We aimed to evaluate the effectiveness and safety of microwave ablation (MWA) for lung metastases from PC.
Methods: This retrospective study analyzed data from PC patients undergoing percutaneous MWA for lung metastases at a Chinese tertiary hospital. Primary outcomes included changes in corrected serum calcium (ΔCSC) and parathyroid hormone (ΔPTH), with influencing factors being assessed. Adverse events were also recorded.
Results: Six patients received 15 MWA procedures for 21 lung metastases. Serum PTH levels decreased by 40.5 ± 21.5%, with a ΔPTH of 321.1 (240.0, 433.0) pg/mL. CSC levels dropped by 0.27 ± 0.25 mmol/L (P = 0.030), normalizing in 66.7% of MWA sessions. Ablated tumor sizes either reduced slightly or stabilized. The time to reach the lowest PTH and CSC levels was 2.0 (1.0, 7.0) days and 3.0 (1.0, 7.0) days, respectively, with effects lasting 31.5 (19.3, 133.0) days for PTH and 14.0 (14.0, 49.0) days for CSC. Fewer metastases (r = -0.539, P = 0.038; r = -0.660, P = 0.007; respectively) and a higher proportion of ablated nodules (r = 0.568, P = 0.027; r = 0.629, P = 0.012; respectively) were associated with greater PTH and CSC reductions. Common complications included mild pneumothorax and mild hemorrhage (20% each), with no adverse events in about half of the sessions.
Conclusion: MWA offers a safe and effective option for treating lung metastases in PC patients when surgery is not feasible.
期刊介绍：
Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology.
Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted.
Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
